Where Privia Health Gr Stands With Analysts
Portfolio Pulse from Benzinga Insights
Privia Health Gr (NASDAQ:PRVA) has received mixed analyst ratings over the last three months, with a recent shift towards more bullish perspectives. The average 12-month price target among analysts is $27.00, marking a 15.99% decline from the previous average. Analyst actions include both new ratings and adjustments to existing ones, with price targets ranging from $21.00 to $37.00. Privia Health is highlighted for its strong financial performance, including a notable revenue growth rate of 20.97%, a net margin of 0.64%, and efficient management reflected in its ROE and ROA figures. The company's low debt-to-equity ratio suggests a conservative financial strategy.
April 22, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Privia Health Gr has seen a mix of analyst ratings, with a recent trend towards more bullish outlooks. The company's strong financial performance, including significant revenue growth and profitability, alongside a conservative debt strategy, positions it favorably in the market.
The shift towards more bullish analyst ratings, combined with Privia Health's strong financial performance indicators such as high revenue growth, profitability, and a conservative debt strategy, suggests a positive short-term impact on PRVA's stock price. The recent adjustments in price targets and ratings reflect an optimistic outlook on the company's future performance, potentially influencing investor sentiment and stock price movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100